Published by Josh White on 22nd December 2025
(Sharecast News) - Shield Therapeutics said on Monday that the US Food and Drug Administration (FDA) has approved an extension of the indication for its iron deficiency treatment Accrufer to include paediatric patients aged 10 years and older, following a priority review.
URL: http://www.digitallook.com/dl/news/story/35583560/...